NCT07342374 is a NA clinical trial of Optimized CTPA Protocol in Pulmonary Artery Embolism, sponsored by Hospital Queen Elizabeth, Malaysia.

Who is sponsoring NCT07342374?

NCT07342374 is sponsored by Hospital Queen Elizabeth, Malaysia.

What drugs are being tested in NCT07342374?

Interventions in NCT07342374: Optimized CTPA Protocol.

What condition does NCT07342374 study?

NCT07342374 studies Pulmonary Artery Embolism, Pulmonary Embolism (PE).

Is NCT07342374 still recruiting?

NCT07342374 is currently completed. Last updated 15 January 2026.

Last reviewed 2026-01-15 · How we verify

NCT07342374

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Repositioning the Bolus Tracking ROI to the Superior Vena Cava in CTPA Facilitates Contrast Volume Reduction

Completed NA Last updated 15 January 2026

What this trial tests

NA trial testing Optimized CTPA Protocol in Pulmonary Artery Embolism in 72 participants. Completed in 16 December 2024.

Timeline

1 February 2023

Primary endpoint
16 December 2024

16 December 2024

Quick facts

Lead sponsor	Hospital Queen Elizabeth, Malaysia
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	72
Start date	1 February 2023
Primary completion	16 December 2024
Estimated completion	16 December 2024
Sites	1 location across Malaysia

Drugs / interventions tested

Optimized CTPA Protocol

Conditions studied

Pulmonary Artery Embolism — all drugs for Pulmonary Artery Embolism →
Pulmonary Embolism (PE) — all drugs for Pulmonary Embolism (PE) →

Sponsor

Hospital Queen Elizabeth, Malaysia

Who can join

Adults 18 to 90, any sex, with Pulmonary Artery Embolism or Pulmonary Embolism (PE). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial evaluates a protocol optimization for Computed Tomography Pulmonary Angiography (CTPA). The study investigates the impact of repositioning the bolus-tracking region-of-interest (ROI) from the standard pulmonary trunk (PT) to the superior vena cava (SVC). The goal is to compensate for the CT scanner's inherent transit delay time (TDT) to better align the scan with the peak arterial phase. By optimizing this timing, the study assesses whether contrast media volume can be safely reduced by 40% (from 50 ml to 30 ml) while maintaining diagnostic image quality and preventing venous contamination.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hospital Queen Elizabeth, Malaysia trials

Trials by the same sponsor.

NCT04512196 — Surgical Site Infection in Perforated Appendicitis After Peritoneal Lavage With Super-oxidised Solution · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07342374 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Queen Elizabeth, Malaysia
Last refreshed: 15 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07342374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing